Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.

Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious diseases, ...

Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria ...

After an investigation, the agency concluded that a case of muscle weakness in one of Novavax’s trials was actually ALS and ...

With flu season underway and new, developing COVID-19 strains, health professionals continue to stress the importance of receiving an updated vaccine. On Oct. 23, the Centers for Disease Control ...

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

Shares of Novavax NVAX lost nearly 20% on Wednesday after the company announced that the FDA has placed a clinical hold on its experimental COVID-19-Influenza Combination (“CIC”) and stand ...

Graeme Sloan / Bloomberg via Getty Images Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.

Editor's note: The headline of this article has been updated to reflect that two vaccine programs are affected by the clinical hold. Novavax’s plans for growth outside of its COVID program have ...

Shares in Novavax fell by as much as one-fifth Wednesday morning after the company disclosed the Food and Drug Administration halted clinical testing of its combination vaccine for COVID-19 and ...

Although Novavax secured the FDA’s authorization for an updated version of its protein-based COVID-19 vaccine toward the end of August, it was delayed compared to the approvals/authorizations ...